163 related articles for article (PubMed ID: 31223125)
1. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
[TBL] [Abstract][Full Text] [Related]
2. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
[TBL] [Abstract][Full Text] [Related]
3. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
[TBL] [Abstract][Full Text] [Related]
4. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
[TBL] [Abstract][Full Text] [Related]
5. [CAPRA score vs minimal residual disease as predictors of biochemical recurrence after radical prostatectomy.].
Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Arch Esp Urol; 2021 Jul; 74(6):554-563. PubMed ID: 34219057
[TBL] [Abstract][Full Text] [Related]
6. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
[TBL] [Abstract][Full Text] [Related]
7. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
[TBL] [Abstract][Full Text] [Related]
9. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
[TBL] [Abstract][Full Text] [Related]
10. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
[TBL] [Abstract][Full Text] [Related]
11. Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2497-2505. PubMed ID: 35901359
[TBL] [Abstract][Full Text] [Related]
12. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
[TBL] [Abstract][Full Text] [Related]
14. Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O
Asian Pac J Cancer Prev; 2015; 16(18):8387-90. PubMed ID: 26745090
[TBL] [Abstract][Full Text] [Related]
15. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
[TBL] [Abstract][Full Text] [Related]
16. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
17. The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.
Murray NP; Reyes E; Salazar A; Lopez MA; Orrego S; Guzman E
Turk J Urol; 2020 May; 46(3):186-195. PubMed ID: 32401703
[TBL] [Abstract][Full Text] [Related]
18. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
[TBL] [Abstract][Full Text] [Related]
19. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
20. Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.
Murray NP; Aedo S; Reyes E; Fuentealba C; Jacob O
Ecancermedicalscience; 2016; 10():671. PubMed ID: 27610197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
